Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,234
Total Claims
$9.6M
Drug Cost
1,180
Beneficiaries
$8,102
Cost/Patient
Risk Score Breakdown 32/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
-92%
Opioid rate vs peers
0.3% vs 3.8% avg
+590%
Cost per patient vs peers
$8,102 vs $1,174 avg
+396%
Brand preference vs peers
44.0% vs 8.9% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 590% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.3%
Opioid Rate
35
Opioid Claims
$721
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 5,323 claims · $9.2M
Generic: 6,785 claims · $375K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 792 | $2.2M |
| Rivaroxaban | 713 | $1.2M |
| Apixaban | 450 | $770K |
| Fluticasone/Umeclidin/Vilanter | 338 | $648K |
| Insulin Aspart | 268 | $538K |
| Insulin Detemir | 296 | $451K |
| Empagliflozin | 168 | $305K |
| Dapagliflozin Propanediol | 180 | $292K |
| Sacubitril/Valsartan | 131 | $267K |
| Linaclotide | 122 | $183K |
| Sitagliptin Phosphate | 78 | $131K |
| Dapaglifloz Propaned/Metformin | 65 | $108K |
| Mirabegron | 72 | $101K |
| Insulin Degludec | 78 | $97K |
| Icosapent Ethyl | 90 | $94K |
Prescribing Profile
Patient Profile
72
Avg Age
57%
Female
1.44
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About